Executive Chairman · NovoCure Ltd (NVCR)

William Doyle

A named executive officer of NovoCure in every fiscal year CompBrief holds from FY2017 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$15,723,701

Salary $772,500Stock awards $13,893,701

FY2019: $8,286,101

1st of 6 named executive officers at NovoCure by FY2020 total.

6 named officers on file for NovoCure, FY2020

William Doyle’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • NVCR’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how NovoCure’s whole pay program stands against its peers

  • NovoCure’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NVCR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2021 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get William Doyle’s full pay file as a PDF — free

More than this page: up to 10 years of William’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

William Doyle compensation by year

NovoCure Summary Compensation Table · all 4 fiscal years held
In US dollars, as NovoCure reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020
Salary$750,000$750,000$750,000$772,500
Bonus$0$0$0$0
Stock awards$10,446,000$587,505$1,654,987$13,893,701
Option awards$11,750,648$2,359,400$4,972,114$0
Non-equity incentive$810,000$843,750$891,000$1,053,000
Pension and deferred compensation$0$0$0$0
All other$18,000$18,000$18,000$4,500
Total$23,774,648$4,558,655$8,286,101$15,723,701

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NovoCure Ltd DEF 14A filed April 27, 2021, accession 0001645113-21-000059, and prior-year filings.

How this page was built: the NovoCure Ltd filed document, accession 0001645113-21-000059. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2021.

$23.8M
$4.6M
$8.3M
$15.7M
FY17
FY18
FY19
FY20
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
PSU200,284$34,657,143—
RSU16,369$2,832,492—
RSU9,259$1,602,177—
RSU4,001$692,333—
Option881,519—$11.85
Option7,809—$83.30
Option115,060—$47.56
Option35,000—$47.56
Option33,714—$47.04
Option101,378—$21.15

Per the Outstanding Equity Awards at Fiscal Year-End table in NovoCure Ltd's FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

6 Form 4 lines since the FY2020 proxy (filed April 27, 2021)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-03-03Grant or award derivative—30,072$0.00288,517
2026-03-03Sale—50,557$12.79349,727
2026-03-03Grant or award—200,000$0.00200,000
2026-03-03Sale—21,330$13.43328,397
2026-03-03Grant or award derivative—258,445$0.00258,445
2026-03-03Grant or award—200,284$0.00400,284

The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

NovoCure’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
William Doyle · this pageExecutive Chairman$15,723,701
Asaf DanzigerChief Executive Officer$8,956,704
Wilhelmus GroenhuysenChief Operating Officer$6,937,924
Pritesh ShahChief Commercial Officer$5,940,598
Todd LongsworthGeneral Counsel$5,149,372
Ashley CordovaChief Financial Officer$3,243,249

Board service

NovoCure board · FY2021–FY2025
Director compensation in US dollars, as NovoCure reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$907,500——$870,465$1,777,965
FY2024$0$0$0$1,418,582$1,418,582
FY2023$0$0$0$1,427,799$1,427,799
FY2022$0$0$627,228$1,524,110$2,151,338
FY2021$0$0$0$780,000$780,000

Each year as the company reported it in NovoCure's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: NovoCure pays directors a $55,000 cash retainer and $375,000 in equity. As stated in NovoCure's FY2025 proxy.

The full NovoCure compensation record

free company brief

This page is one person within NovoCure's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the NovoCure proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NovoCure's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

William Doyle's compensation dossier · One-time report. No refunds.